Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Non-Current Deffered Revenue (2023 - 2024)

Gain Therapeutics (GANX) has 2 years of Non-Current Deffered Revenue data on record, last reported at $47441.0 in Q4 2024.

  • For Q4 2024, Non-Current Deffered Revenue fell 49.95% year-over-year to $47441.0; the TTM value through Dec 2024 reached $47441.0, down 49.95%, while the annual FY2024 figure was $47441.0, 49.95% down from the prior year.
  • Non-Current Deffered Revenue reached $47441.0 in Q4 2024 per GANX's latest filing, down from $65869.0 in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $608982.0 in Q2 2023 and bottomed at $47441.0 in Q4 2024.